RxDoctor Payments Data

David Huang

Infectious Disease · Houston, TXNPI 1215943865

Payments from drug & device makers

What this record shows

Madrigal Pharmaceuticals accounts for 91.0% of it on its own, with 3 other manufacturers making up the rest.

$1,514in general payments, 2019–2025

Across 16 payments — averaging $94.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$1K
  • Ipsen Biopharmaceuticals, Inc$73
  • Orphalan Inc$32
  • Gilead$30
$882,118in research payments, 2019–2025

Across 189 payments — averaging $4667.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Madrigal Pharmaceuticals$522K
  • Boehringer Ingelheim International GmbH$291K
  • Astrazeneca UK Limited$35K
  • Boehringer Ingelheim$30K
  • Eli Lilly$4K

What the payments were for

  • Travel & lodging$83755%
  • Food & beverage$67745%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Madrigal Pharmaceuticals11$1,379
Ipsen Biopharmaceuticals, Inc3$73
Orphalan Inc1$32
Gilead1$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,514 in reported general payments places this provider in the 65th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas

Other infectious disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →